<DOC>
	<DOCNO>NCT02818686</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) TD-1473 subject moderately-to-severely active UC 28 day . This exploratory study also serve signal seek endeavor demonstrate biologic effect associate TD-1473 biomarker analysis clinical , endoscopic , histologic assessment .</brief_summary>
	<brief_title>TD-1473 Active Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Has history ulcerative colitis diagnosis least 3 month prior screen Is intolerant , refractory , partially responsive aminosalicylates , corticosteroid , immunomodulators , biologics . If subject currently receive oral aminosalicylate , eligible stay dose aminosalicylate provide dose stable least 2 week prior screen . If subject currently receive oral corticosteroid , eligible dose equivalent less prednisone 20 mg/day budesonide 9 mg/day stable least 2 week prior screen sigmoidoscopy subject corticosteroid 2 week . Has rectal bleeding score ≥ 1 bowel frequency score ≥ 1 patientreported outcome 2 ( PRO2 ) screen sigmoidoscopy day Day 1 addition modify Mayo endoscopic subscore ≥ 2 screen Women childbearing potential must negative pregnancy test either abstain sexual intercourse use highly effective method birth control Willing able give inform consent Additional inclusion criterion apply Has fulminant colitis , toxic megacolon , primary sclerosing cholangitis , Crohn 's disease , history colitisassociated colonic dysplasia , active peptic ulcer disease Medications exclusion : ) azathioprine , 6mercaptopurine , methotrexate within 28 day prior Day 1 , b ) adalimumab , infliximab , golimumab , etanercept , certolizumab within 60 day prior Day 1 , c ) intravenous corticosteroid within 14 day prior Day 1 , ) topical mesalamine steroid ( i.e. , enema suppository ) within 14 day prior Day 1 , e ) prior exposure mycophenolic acid , tacrolimus , sirolimus , cyclosporine , natalizumab , rituximab , efalizumab , fingolimod , thalidomide , f ) NSAIDs daily basis , g ) tofacitinib within 60 day prior Day 1 ; h ) vedolizumab within 120 day prior Day 1 Has current bacterial , parasitic , fungal , viral infection Is positive hepatitis A , B C , HIV tuberculosis Has clinically significant abnormality laboratory evaluation Participated another clinical trial investigational drug ( medical device ) within 30 day prior screen ( within 60 day prior screen investigational drug biologic another Janus kinase ( JAK ) inhibitor , currently participate another trial investigational drug ( medical device ) Use prescription medication start dose adjustment within 4 week prior study enrollment , overthecounter medication supplement start dose adjustment within 2 week prior study enrollment . Antidiarrheal medication allow dose stable least 2 week prior study enrollment Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ulcerative Colitis , Active Moderate Severe</keyword>
</DOC>